NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NRG Oncology
UNICANCER
Shanghai JMT-Bio Inc.
Peking University
Sun Yat-sen University
Sun Yat-sen University
NRG Oncology
Ukrainian Society of Clinical Oncology
Eurofarma Laboratorios S.A.